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TO THE EDITOR
Segmental overgrowth syndromes, con-
sisting of a spectrum of disorders with
vascular, cutaneous, and skeletal abnor-
malities, are sporadic, nonhereditary
disorders (Lindhurst et al., 2011;
Biesecker and Spinner, 2013). It was
originally postulated by Happle (1987)
that such disorders arise as a result of
mosaic somatic mutations and that
complete heterozygosity for the causal
mutation could be either lethal to the
affected individual or the affected
person would be incapable of germline
transmission. The prototype of the
mosaic postnatal overgrowth syndromes
is the Proteus syndrome commonly mani-
festing with connective tissue nevi and
bone overgrowth, but the central nervous
system and the eyes can also be affected.
The tissue overgrowth in Proteus syn-
drome is noncongenital and progressive,
the diagnosis is often delayed, and the
cases can be difficult to manage. The
Proteus syndrome is caused by hetero-
zygous activating mutations in the AKT1
gene (Biesecker, 2006).
A condition in differential diagnosis
with the Proteus syndrome is the
recently described disorder, CLOVES
syndrome (congenital lipomatous asym-
metric overgrowth of the trunk with
lymphatic, capillary, venous, andAccepted article preview online 23 January 2015; published online 19 February 2015
Abbreviations: CLOVES, congenital lipomatous overgrowth with vascular malformations, epidermal nevi
and skeletal abnormalities; MCAP, megalencephaly/hemimegalencephaly-capillary malformation
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combined-type vascular malformations,
epidermal nevi, and skeletal abnormal-
ities; Kurek et al., 2012). This syndrome
has overlapping features with megalen-
cephaly/hemimegalencephaly-capillary
malformation (MCAP) syndrome and
isolated macrodactyly, as well as with
fibroadipose hyperplasia, which is
characterized by segmental overgrowth
of fibrous and adipose tissue and bone.
In fact, these conditions appear to
represent a spectrum of phenotypic
manifestations with overlapping
features, and it has been suggested that
they belong to the PIK3CA-related
overgrowth spectrum (Keppler-Noreuil
et al., 2014). These syndromes are
caused by somatic activating mutations
in the PIK3CA gene in the pathway
shared with AKT1. Because of the
overlapping clinical features, the
precise diagnosis is often difficult, and
identification of a specific mutation in
the affected tissues is required for
accurate diagnosis (Mirzaa et al.,
2013). In this report, we describe a
patient with segmental hypertrophy
initially considered to have the Proteus
syndrome, but the mutation analysis
confirmed the diagnosis of fibroadipose
hyperpoplasia.
The patient is a 3-year and 4-month-
old girl born at term by elective cesar-
ean section after a normal pregnancy.
She is the first child of healthy, non-
consanguineous parents with no signifi-
cant family history. Her birth weight
was 3.5 kg (B50th percentile) and birth
length was 55 cm (B97th percentile).
She was initially noted to have conge-
nital overgrowth in her right lower limb,
and there was progressive growth of the
right leg and foot (Figure 1). The over-
growth was a mixture of adipose and
fibrous tissue and had a mosaic distribu-
tion. Ultrasound revealed subcutaneous
multicystic lesions in the left lower
flank, with power doppler suggestive of
lymphangioma with an approximate
diameter of 3.54.5 cm at 2 years of
age. The other abnormalities included
visceral herniation in the left side of her
body. There were also multiple cafe´-au-
lait-like spots and hyperpigmentation on
the abdomen and lower limb. There was
no evidence of abdominal vascular mal-
formations, or spleen/thymus visceral
overgrowth on portable color double
imaging. Moreover, her liver, biliary
tract, and both kidneys were normal
on ultrasound examination. She had
normal intellectual development and
there was no history of hypotonia and
seizures, features of MCAP syndrome.
The patient did not have cerebriform
connective tissue nevi, a characteristic
feature of Proteus syndrome. Collec-
tively, the clinical findings favored the
diagnosis of fibroadipose hyperplasia
(Lindhurst et al., 2012).
To confirm the diagnosis of fibroadi-
pose hyperplasia, written informed con-
sent was obtained and DNA was
isolated from peripheral blood leuko-
cytes as well as from tissue surgically
obtained from the affected and unaf-
fected areas of skin on the right foot.
Sequencing of PIK3CA revealed the
presence of the mutation c.1624G-A
(p.Glu542Lys) in the affected tissue
(Figure 2a); this mutation has been
reported previously in patients with
somatic overgrowth syndrome (Lindhurst
et al., 2012). This sequence variant is
not present in the SNP databases-
Exome Sequence Variant Server (evs.gs.
washington.edu/EVS/) and 1,000
Genome Project (www.1000genomes.
org), and bioinformatics analysis by
PolyPhen-2 and SIFT programs predic-
ted that it is ‘‘Probably Damaging’’
(score 0.99) and ‘‘Damaging’’ (score
0.11), respectively. The Glu542 residue
Figure 1. Clinical features of progressive congenital segmental overgrowth. (a) The patient at 3 years and 4 months of age with massive overgrowth in her right
leg and subcutaneous tissue on the truncal area. (b) Overgrowth of the right foot and progressive macrodactyly in the left foot at 3 years and 4 months and (c) at 2
years of age. (d) Posterior view showing the right hemihyperplasia with a leg length discrepancy at 3 years and 4 months of age. (e) X-ray of the feet showing
overgrowth of the right foot at 2 years of age. (The patient’s guardians gave permission to publish photographs of the patient).
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is conserved through evolution among
species between human and the
pufferfish (Figure 2b). A consequence
of the p.Glu542Lys mutation is change
in charge and size of this residue, which
is predicted to be involved in multimeric
assembly of the protein complex
(Figure 2c). These conformational and
functional changes are accompanied by
activation of PI3K leading to cell
proliferation (Venselaar et al., 2010).
The estimated proportion of the mutant
allele of the total PIK3CA was 24.5±
0.7% (mean±SD) as determined by the
ratio of peak areas of wild-type and
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Figure 2. Mutational analysis of the PIK3CA gene in blood as well as in affected and normal tissue, and characterization of the p.Glu542Lys mutation. (a) DNA
from the peripheral blood is negative for the mutation, whereas a c.1624G4A mutation (arrow; p.Glu542Lys) was found in the PIK3CA gene in a biopsy from the
affected area of skin in the right foot. The biopsy from normal skin tissue is negative for the mutation. (b) The wild-type Glu542 is evolutionarily conserved (red
arrow). (c) Three-dimensional prediction of the consequences of the mutation. Green represents the wild-type (Glu542) residue and red corresponds to the mutant
(Lys542) residue. (d) Schematic pathway of PI3K, AKT, and mTOR signaling, indicating inhibition of mTOR by rapamycin.
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mutant alleles in five separate analyses.
DNA from peripheral blood and normal
skin biopsy was negative for this muta-
tion. Thus, this amino acid substitution is
a somatic mutation in a mosaic cell
population, consistent with the diagno-
sis of fibroadipose hyperplasia. This
diagnosis was further supported by
exclusion of the Proteus syndrome dia-
gnosis by sequencing of the AKT1 gene.
Specifically, the recurrent, and the only
mutation disclosed in Proteus syndrome
as of to date, c.49G4A (p.Glu17Lys),
the activating mutation in exon 1 of
AKT1, was not present in our patient’s
DNA (Wee et al., 2014).
Fibroadipose hyperplasia overgrowth
syndrome was first reported in 2012 as a
PIK3CA-related condition (Lindhurst
et al., 2012). So far, over 20 distinct
mutations in the PIK3CA gene have
been reported in the PIK3CA-related
overgrowth spectrum, three of them
being reported in fibroadipose hyper-
plasia (Mirzaa et al., 2013). Among
these mutations, those affecting codon
1,047, specifically p.His1047Arg and
p.His1047Leu, are the most prevalent
(Keppler-Noreuil et al., 2014). The
mutations are mosaic, and the ratio of
the mutant versus wild-type allele
reflects the mixture of cells in a
mosaic pattern (Lindhurst et al., 2012;
Keppler-Noreuil et al., 2014). The
PIK3CA gene encodes the 110-kD
catalytic alpha subunit of PI3K, which
in response to tyrosine kinase receptor
ligand binding is activated and converts
phosphatidylinositol (4,5)-bisphosphate
to phosphatidylinositol (3,4,5)-triphos-
phate. This leads to activation of AKT
to initiate downstream cellular effects
(Yuan and Cantley, 2008) (Figure 2d).
In addition to fibroadipose hyperpla-
sia, individuals with both somatic and
germline loss-of-function mutations of
PTEN, a negative regulator of PI3K, have
symmetric soft-tissue overgrowth in
association with vascular abnormalities
as part of Cowden syndrome (Marsh
et al., 2008). Missense mutations in
each of the AKT family of proteins
have been reported in individuals
with the Proteus syndrome (AKT1), in
patients with asymmetric overgrowth
and hyperglycemia (AKT2), and in
individuals with hemimegalencephaly
(AKT3; Hussain et al., 2011; Poduri
et al., 2012; Riviere et al., 2012). The
spectrum of phenotypic presentations as
a result of PIK3CA activation mutations
has been suggested to reflect the
developmental stage at which the
mutation arises. It should be noted that
the PI3K resides upstream of AKT and
this pathway leads to activation of cell
proliferation through mTOR (Figure 2d).
Thus, inhibition of mTOR by rapamycin
could potentially be useful for the treat-
ment of overgrowth sydromes (Marsh
et al., 2008).
In summary, we present a clinically
challenging case with mosaic over-
growth, and mutation analysis identified
a recurrent missense mutation,
p.Glu542Lys, in the PIK3CA gene, in
the affected tissue, confirming the diag-
nosis of fibroadipose hyperplasia. This
illustrative case should make clinicians
aware of the molecularly based differ-
ential diagnosis of tissue overgrowth
syndromes.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Lida Sharifi-Rad, Children’s Hospital
Medical Center, Pediatric Center of Excellence,
Tehran, for her assistance in sampling of the
patient. Carol Kelly assisted in manuscript pre-
paration. Leslie G Biesecker and Marjorie J
Lindhurst, National Institutes of Health, provided
helpful information.
Leila Youssefian1,2,5,
Hassan Vahidnezhad1,2,3,5,
Taghi Baghdadi4,5, Alireza Ghaznavi4,
Qiaoli Li2, Mina Tabrizi1 and Jouni Uitto2
1Department of Medical Genetics, School
of Medicine, Tehran University of Medical
Sciences, Tehran, Iran; 2Department of
Dermatology and Cutaneous Biology, Thomas
Jefferson University, Philadelphia,
Pennsylvania, USA; 3Department of Molecular
Medicine, Biotechnology Research Center,
Pasteur Institute of Iran, Tehran, Iran and
4Department of Orthopedic Surgery, Imam
Khomeini Hospital, Tehran University of
Medical Sciences, Tehran, Iran
E-mail: Jouni.Uitto@Jefferson.edu
5These authors contributed equally to this work.
REFERENCES
Biesecker L (2006) The challenges of Proteus
syndrome: diagnosis and management. Eur J
Hum Genet 14:1151–7
Biesecker LG, Spinner NB (2013) A genomic view
of mosaicism and human disease. Nat Rev
Genet 14:307–20
Happle R (1987) Lethal genes surviving by mosai-
cism: a possible explanation for sporadic birth
defects involving the skin. J Am Acad Derma-
tol 16:899–906
Hussain K, Challis B, Rocha N et al. (2011) An
activating mutation of AKT2 and human
hypoglycemia. Science 334:474
Keppler-Noreuil KM, Sapp JC, Lindhurst MJ et al.
(2014) Clinical delineation and natural history
of the PIK3CA-related overgrowth spectrum.
Am J Med Genet A 164A:1713–33
Kurek KC, Luks VL, Ayturk UM et al. (2012)
Somatic mosaic activating mutations in
PIK3CA cause CLOVES syndrome. Am J
Hum Genet 90:1108–15
Lindhurst MJ, Parker VE, Payne F et al. (2012)
Mosaic overgrowth with fibroadipose
hyperplasia is caused by somatic acti-
vating mutations in PIK3CA. Nat Genet
44:928–33
Lindhurst MJ, Sapp JC, Teer JK et al. (2011) A
mosaic activating mutation in AKT1 asso-
ciated with the Proteus syndrome. N Engl J
Med 365:611–9
Marsh DJ, Trahair TN, Martin JL et al. (2008)
Rapamycin treatment for a child with germ-
line PTEN mutation. Nat Clin Pract Oncol
5:357–61
Mirzaa GM, Riviere JB, Dobyns WB (2013) Mega-
lencephaly syndromes and activating muta-
tions in the PI3K-AKT pathway: MPPH and
MCAP. Am J Med Genet C Semin Med Genet
163C:122–30
Poduri A, Evrony GD, Cai X et al. (2012)
Somatic activation of AKT3 causes hemi-
spheric developmental brain malformations.
Neuron 74:41–8
Riviere JB, Mirzaa GM, O’Roak BJ et al. (2012) De
novo germline and postzygotic mutations in
AKT3, PIK3R2 and PIK3CA cause a spectrum
of related megalencephaly syndromes. Nat
Genet 44:934–40
Venselaar H, te Beek TA, Kuipers RK et al. (2010)
Protein structure analysis of mutations
causing inheritable diseases. An e-Science
approach with life scientist friendly inter-
faces. BMC Bioinformatics 11:548
Wee JS, Mortimer PS, Lindhurst MJ et al. (2014)
A limited form of Proteus syndrome
with bilateral plantar cerebriform collageno-
mas and varicose veins secondary to a
mosaic AKT1 mutation. JAMA Dermatol
150:990–3
Yuan TL, Cantley LC (2008) PI3K pathway altera-
tions in cancer: variations on a theme. Onco-
gene 27:5497–510
L Youssefian et al.
Segmental Overgrowth Syndromes
www.jidonline.org 1453
